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Introduction 
Substantial evidence is recently becoming available that brominated flame retardants (BFRs) are 
potential endocrine disruptorsi. The toxicological profile of BFRs, however, is too incomplete and 
insufficient to perform human and ecological risk assessment. To fill these gaps, the EU funded 
research program FIREii was started in December 2002. This program aims at the identification and 
toxicological characterization of the most potent and environmentally relevant BFRs and their 
possible risk for human and wildlife health. As part of a hazard identification approach, twenty-
seven BFRs have been selected within the framework of FIRE for pre-screening their endocrine-
disrupting potencies. Selection of test compounds was based on a maximal variation in physico-
chemical characteristics of BFRs within the test set, allowing the establishment of quantitative 
structure-activity relationships (QSARs)iii,iv. In addition, environmental relevance (e.g. high 
production volumes and persistence) and availability for testing were used as selection criteria. 
BFRs were tested in seven different in vitro bioassays for their potency to interfere via estrogenic, 
thyroidal, androgenic, progestagenic, and Ah-receptor mediated pathways. Metabolisation rates of 
BFRs were determined using phenobarbital-induced rat liver microsomes. Finally, the endocrine 
disrupting potency of the metabolites was determined in the same in vitro bio-assays and compared 
to the potency of the parent compounds. 
 
Material and Methods 
Nineteen out of the twenty-seven test compounds were poly-brominated diphenyl ethers (PBDEs), 
i.e. triBDEs 19, 28, 38, 39, tetraBDEs 47, 49, 79, pentaBDEs 99, 100, 127, hexaBDEs 153, 155, 
169, heptaBDEs 181, 183, 185, 190, nona-BDE 206, and deca-BDE 209. Three 
hexabromocyclododecane (HBCDD) isomers (alpha, beta, and gamma) and a HBCDD technical 
mixture (HBCDD-TM; about 90% gamma isomer) were included in the test set, as well as the 
hydroxylated compounds tetrabromobisphenol-A (TBBPA), 2,4,6-tribromophenol (246TBP), and 
ortho-hydroxylated BDE 47 (6OH-BDE 47). The test set was completed by TBBPA-
bis(2,3)dibromopropylether (TBBPA-DBPE). BDEs 28, 47, 49, 99, 100, 153, 155, 169, 181, 183, 
190, 206, and 209 and 6OH-BDE47 and 246TBP were obtained from Stockholm University (G. 
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Marsh/Å. Bergman), BDEs 19, 38, 39, 79, 127, and 185 were bought from Accu Standard. TBBPA 
was obtained from Aldrich, HBCDD TM from Dead Sea Bromine Group, HBCDD isomers from 
Cambridge Isotope Laboratories, and TBBPA-DBPE from RIVO IJmuiden (P. Leonards). 
 
Ah-receptor (DR), estrogen receptor (ER), androgen receptor (AR) and progesterone receptor (PR) 
agonistic and antagonistic activities of the test compounds were detemined in CALUX® reporter 
gene bioassays (BioDetection Systems, NL) as described elsewherev,vi,vii. Two assays were used to 
test thyroid disrupting potency. Competition with thyroid hormone precursor thyroxine (T4) for T4 
binding sites on carrier proteins such as transthyretin (TTR) was measured in the T4-TTR 
competition assayviii and thyroid hormone triiodothyronine (T3) mimicking or inhibiting potency in 
the T-Screenix. Finally, the potency to inhibit estradiol sulphation was tested in the E2SULT 
inhibition assayx. 
 
Based on their in vitro endocrine disrupting potency, BFRs were classified for each bio-assay. 
Using hierarchical cluster analyses and principal component analysis (PCA), pattern recognition 
was performed to find common features among the tested BFRs depending on common 
toxicological profiles determined in the bio-assays. 
 
Endocrine disrupting potency of the test set was not only determined for the parent compounds, but 
also for their metabolites. Metabolites were prepared by incubating BFRs in hepatic microsomal 
suspensions from phenobarbital-induced male Wistar rats with NADPH as electron donor at 37°C. 
To estimate optimum incubation periods, mixtures of three to six BFRs were incubated for 0, 15, 
30, and 90 minutes, and the decrease of parent compound in each mixture was followed in time by 
GC-MS analysis.  BFRs for which significantly decreased levels of parent compounds were found, 
were then incubated individually to prepare metabolite-containing microsomal extracts for testing 
in the in vitro assays described above.  
 
Results and discussion 
Out of the total set of 27 BFRs tested for 12 different endpoints, highest responses were found in 
the AR CALUX® bioassay, the T4-TTR competition assay and the E2-SULT inhibition assay. 
Whereas none of the BFRs tested acted as AR-agonists, BDE 19 and BDE 100 were extremely 
potent AR-antagonists with IC50-values <0.1 µM. Together with BDEs 47 and 49, these BFRs had 
an anti-androgenic potency higher than the anti-androgenic drug flutamide (IC50 = 1.3 µM) that was 
used as a reference compound. Common structural features among these most potent AR-
antagonists are the di-ortho (2,6) or ortho-para (2,4) bromine substitution on the one phenyl ring 
and the presence of an ortho bromine atom (2’) on the other phenyl ring. 
 
In the T4-TTR-assay, TBBPA and 246TPB were very potent T4 competitors with a TTR-binding 
affinity comparable to T4. TBBPA and 246TBP were also the most potent estradiol 
sulfotranseferase inhibitors (IC50 <0.1 µM), being one order of magnitude lower than the positive 
control pentachlorophenol. Although the other hydroxylated test compound 6OH-BDE47 was less 
potent than 246TBP and TBBPA in both the TTR and E2SULT assay (IC50 = 1-10 µM), it was still 
the most potent of the rest of the test set, indicating that the presence of a hydroxyl-group clearly 
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In the other in vitro bioassays, none of the tested BFRs had potencies with similar EC50-values <0.1 
µM. Still, these assays yielded plenty of information to discriminate between BFRs with high and 
low endocrine disrupting potency. With respect to PBDEs for instance, ER agonism was found for 
some low-brominated BDEs (≤ hexa-BDEs) whereas ER-antagonism was found only for high-
brominated (≥ hepta-BDEs). Similar to the AR CALUX® bioassay, highest PR-antagonistic 
response was found for BDE 19 in the PR CALUX® bioassay, but the anti-PR potency of BDE 19 
(IC50=0.8 µM) was about 4000 times lower than for the breast cancer drug RU486, which was used 
as a reference compound. The highest DR-agonistic potency was found for BDEs 38, 79, 153 and 
190 (EC50 = 0.1-1.0 µM). Especially the relatively high DR-agonistic potency of di-ortho-
substituted BDE153 (2,2’,4,4’,5,5’) is a remarkable result, given the lack of DR-activating potency 
reported for the identically substituted polychlorinated biphenyl (PCB 153)xi. BDE 153 probably 
fits better in the DR-pocket than PCB 153 due to the presence of an ether-bridge between the two 
phenyl-rings, which is absent in PCB153.  
 
Using pattern recognition methods (i.e. cluster analysis and PCA), the hydroxylated BFRs TBBPA 
and 246TBP with high TTR-binding and E2SULT inhibiting potency could clearly be distinguished 
from the 2,2’-substituted BDEs 19, 49, and 100 with high AR- and PR-antagonistic potency. 
Moreover, TBBPA-DBPE and BDEs 169 and 209 were clearly recognized as a group of 
compounds with almost no potency in any of the assays performed. For the remaining BFRs, ER-
agonistic and ER-antagonistic responses seem to be the most discriminating factor, separating 
hepta-brominated BDEs, HBCDD TM, and gamma-HBCDD with low anti-estrogenic potency 
from lower brominated BDEs and alpha and beta isomers of HBCDD with no or very low 
estrogenic potency. 
 
For twenty BFRs out of a total of twenty-seven tested in the in vitro metabolisation experiments, 
less than 80% of the original parent compound could be recovered after 90 minutes of incubation, 
indicating that more than 20% of the compound had been metabolized. Highest metabolisation 
rates were found for BDEs 19, 38 and 49 for which less than 10% of the parent compound could be 
recovered after 15 minutes of incubation. No or hardly any metabolisation was found for BDEs 
127, 153, 169, 181, 183, 190, 206, and 209. In general, BDEs were somewhat easier oxidized by 
microsomal cytochrome P450 (CYP) than the corresponding PCBs, given the time-dependent 
decrease found for BDEs 47, 99, 100, and especially 155, that were supposed to be resistant to CYP 
metabolisation based on similar experiences with their PCB equivalentsxii. 
 
So far, the endocrine disrupting potency of metabolites has only been tested in T4-TTR competition 
assay and in AR, PR, and ER CALUX® bioassays. Compared to the parent compounds, a higher 
TTR-binding capacity was found for all metabolized BDEs, with highest T4-TTR competing 
potency for BDE 49 metabolites. Metabolites of BDEs 19, 28, 38, 39 and 155, of which the parent 
compounds had no TTR-binding capacity at all, showed largest increases in toxic potencies, with 
EC50 values equivalent to 0.1-1.0 µM of parent compound. After metabolisation, T4-TTR 
competing potency had decreased for TBBPA and 246TBP, and no more competing activity was 
found for TBBPA-DBPE and the alpha and beta isomers of HBCDD. After metabolisation, an 
increase in anti-androgenic potency was found for TBBPA-DBPE and in anti-estrogenic potency 
for BDE 28, whereas the parent compounds did not show any activity for these endpoints. For all 
other compounds tested in AR, PR, and ER CALUX® bioassays, similar antagonistic results were 
found for the metabolite fraction compared to the parent compounds. With respect to ER-agonistic 
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responses, no activity was found for any of the metabolite fractions except for a small response 
from BDE 185 metabolites.  
 
Conclusions 
Our results clearly demonstrate that brominated flame retardants as well as their oxidized 
metabolites can interfere with endocrine pathways. We can distinguish separate groups of BFRs 
based on their toxicological profile. Highest anti-AR potency was found for di-ortho (2,2’) 
substituted BDEs, and highest T4-TTR competing and E2-SULT inhibiting potency for 
hydroxylated BFRs. For these in vitro endocrine pathways, potencies were higher than for clinical 
drugs, natural ligands, or positive controls. Endocrine disrupting potencies of the BFRs changed 
drastically after metabolisation of the parent compounds. This was most obvious in the T4-TTR 
competition assay. After completion, the in vitro dataset will be used within the FIRE program to 
establish QSARs and to select a number of compounds for in vivo testing. This will provide a 
valuable endocrine disruption based data-set of the environmentally most relevant BFRs for human 
and ecological risk assessment. 
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